Thalassemia and sickle cell anaemia are common genetic disorders in India. Early testing, prenatal screening, and improved ...

LAHORE: The Punjab government has made genetic testing, including for thalassemia and other diseases, mandatory for students ...

It would be for the management of patients with Thalassemia and Sickle Cell Disease responding to a request from Nepal. The Tribune, now published from Chandigarh, started publication on February ...

In Punjab, it has been made mandatory for all students to undergo screening for thalassemia and other genetic disorders at ...

The following is a summary of “Evaluated NSUN3 in reticulocytes from HbH-CS disease that reflects cellular stress in ...

U.S. Regulatory Filing Under Active Review for Approval of PYRUKYND® (mitapivat) in Thalassemia, with PDUFA Goal Date of September 7, 2025 – – Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease ...

India has delivered a $2 million consignment of vaccines to Nepal to combat Sickle Cell Disease and Thalassemia, enhancing the country's healthcare efforts. The donation underscores the longstanding ...

Amid a reckoning for the gene therapy field, Vertex Pharmaceuticals has joined a growing list of companies paring back their ...

Agios Pharmaceuticals Inc (AGIO) reports a 6% revenue increase and outlines promising pipeline developments, despite facing ...

As per the release from the Indian Embassy in Kathmandu the first consignment of vaccines is worth USD 2 million. It would be for the management of patients with Thalassemia and Sickle Cell Disease ...

PYRUKYND, a pyruvate kinase activator, remains the flagship product with multi-billion-dollar potential. Agios is targeting a U.S. approval for thalassemia by September 7, 2025, and a sickle cell ...